International Journal of Hematology

, Volume 75, Issue 4, pp 385–387 | Cite as

Antithymocyte Globulin in the Treatment of D-Penicillamine—Induced Aplastic Anemia

  • Haruki Kondo
  • Kanae Narita
Review Article


A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described. Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months, respectively, after treatment, and blood transfusion or other therapies were not necessary in a follow-up period of more than 2 years. Use of antithymocyte globulin may be the optimal treatment of D-penicillamine—induced aplastic anemia.

Key words

Antithymocyte globulin Aplastic anemia D-penicillamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weiss AS, Markenson JA,Weiss MS, Kammerer WH.Toxicity of D-penicillamine in rheumatoid arthritis: a report of 63 patients including two with aplastic anemia and one with nephrotic syndrome.Am J Med. 1978;64:114–120.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Fishel B, Tishler M, Caspi D, Yaron M. Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis.Ann Rheum Dis. 1989;48:609–610.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Camitta BM, Doney K. Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results.Am J Paediatr Hematol Oncol. 1990;124:411–424.CrossRefGoogle Scholar
  4. 4.
    Miller WJ, Branda RF, Flynn PJ, et al. Antithymocyte globulin treatment of severe aplastic anemia.Br J Haematol. 1983;55:17–25.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Alvara-Gracia JM, Castaneda-Sanz S, Arranz R, Ariza A, Sabanco P, Ossorio C. Antithymocyte globulin in the treatment of gold induced severe aplastic anemia.J Rheumatol. 1988;15:43–45.Google Scholar
  6. 6.
    Yaffe IA. Penicillamine. In: McCarty DJ, ed.Arthritis and Allied Conditions. 10th ed. Philadelphia, Pa: Lea & Febiger; 1985: 502–511.Google Scholar
  7. 7.
    Chandra P, Koch W. Cited report of symposium on penicillamine.Ann Rheum Dis. 1975;34:273–274.CrossRefGoogle Scholar
  8. 8.
    Panayi GS, Wooley P, Batchlor JR. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs.Br J Med. 1987;2:1326–1328.CrossRefGoogle Scholar
  9. 9.
    Lipsky PE. Mechanisms of action of slow-acting drugs in rheumatoid arthritis.Clin Exp Rheumatol. 1989;7(suppl 3):S177-S180.PubMedGoogle Scholar
  10. 10.
    Romain PL, Burmester CJR, Enlow RW, Winchester RJ. Multiple abnormalities in immunoregulatory function of synovial compartment T cells in patients with rheumatoid arthritis: recognition of helper augmentation effects.Rheumatol Int. 1982;2:121–127.CrossRefPubMedGoogle Scholar
  11. 11.
    Gluckman E, Marmont A, Speck B, Gordon-Smith EC. Immuno-suppressive treatment of aplastic anemia as an alternative treatment of bone marrow transplantation.Semin Hematol. 1984;21:11–19.PubMedGoogle Scholar
  12. 12.
    Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia.N Eng J Med. 1997;336:1365–1372.CrossRefGoogle Scholar
  13. 13.
    Barnett AJ, Whiteside MG. Marrow aplasia and penicillamine.Lancet. 1976;2:682–683.CrossRefGoogle Scholar
  14. 14.
    Lowenthal RM, Chohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation.J Rheumatol. 1993;20:137–140.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  1. 1.Division of Haematology and Oncology, Department of MedicineShimizu Kohsei HospitalShimizu-city, ShizuokaJapan

Personalised recommendations